Rexahn Pharmaceuticals, Inc. (RNN) Reports First Quarter 2014 Financial Results And Pipeline Update
5/15/2014 9:56:42 AM
Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and financial results for the quarter ended March 31, 2014.
“We continue to enroll patients in each of our three clinical trials as expected, and as planned for,” stated Rexahn’s Chief Executive Officer, Peter D Suzdak, Ph.D. “By the end of 2014, we expect to achieve key milestones in each trial.
Help employers find you! Check out all the jobs and post your resume.
comments powered by